bioAffinity Technologies, Inc.

10-Year Study

BIAF.US · Healthcare · US · Common Stock

Executive Summary: bioAffinity Technologies, Inc. has compounded at -61.9% annually over the last 10 years, with a maximum drawdown of 98.8% and an annualized volatility of 275.1%.

1Y CAGR
-70.3%
3Y CAGR
-64.1%
5Y CAGR
-61.9%
10Y CAGR
-61.9%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
98.8%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.04
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.13
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
173.2%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +133.9%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -95.7%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
25%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-3.4-7.0261.3-27.9————————133.9%
2025-16.5-34.2-48.080.8-40.42.510.5-23.7-59.2-17.2-38.8-21.3-95.7%
20246.747.8-12.921.3-2.0-10.015.3-39.838.7-31.2-15.0-25.1-38.1%
202363.1-34.911.23.2-6.20.0-3.8-1.7-32.78.431.5-11.4-8.1%
2022—————————-2.1-5.3-40.7-45.0%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 275.1%. The dominant macroeconomic risk driver is SHV.US, accounting for 66.9% of variance. Idiosyncratic stock-specific factors contribute 10.5%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2022-09-0110000
2022-10-019793.814090626018
2022-11-019278.350191119385
2022-12-015498.281594737413
2023-01-018969.072200986735
2023-02-015841.924194408502
2023-03-016494.8452211764015
2023-04-016701.030693586223
2023-05-016288.65974876658
2023-06-016288.65974876658
2023-07-016048.109666818322
2023-08-015945.017149095493
2023-09-013999.9996504286705
2023-10-014336.769677763401
2023-11-015704.467067147234
2023-12-015054.982763511675
2024-01-015395.188640050423
2024-02-017972.508137583585
2024-03-016941.58033857032
2024-04-018419.243691941665
2024-05-018247.42239210612
2024-06-017422.680502466837
2024-07-018556.70038223877
2024-08-015154.638995066325
2024-09-017147.7662479443015
2024-10-014914.089350082228
2024-11-014175.257673396556
2024-12-013127.1475696140715
2025-01-012611.683670107439
2025-02-011718.2129983554416
2025-03-01893.4707809930377
2025-04-011615.1202621505315
2025-05-01962.1992353826312
2025-06-01986.254221729249
2025-07-011089.3470671751998
2025-08-01831.6151174218835
2025-09-01339.0607027117821
2025-10-01280.6414618601075
2025-11-01171.82129983554415
2025-12-01135.16608319570418
2026-01-01130.58418623639795
2026-02-01121.4203852171179
2026-03-01438.7170522467561
2026-04-01316.1511916974012
Annual Return Matrix
YearAnnual Return
2023-0.08062497774759925
2024-0.38137324776125336
2025-0.9567765574899347
20261.3389831548174143
Total Factor Risk
2.7514766622153455
VTI.US Exposure
0.025100076974947354
VEA.US Exposure
0.006964031739782038
VWO.US Exposure
0.01463486003473392
QQQ.US Exposure
-0.0017053014222712685
VTV.US Exposure
0.05584102951518444
IJR.US Exposure
-8.036730689679153e-7
QUAL.US Exposure
0.0027587682103052727
SHV.US Exposure
0.66929774465297
TLT.US Exposure
0.007789509457147266
LQD.US Exposure
0.02168769907402692
HYG.US Exposure
0.035134953466165686
GLD.US Exposure
0.00015563335529252486
USO.US Exposure
0.010983412142797537
VNQ.US Exposure
0.021624284798281403
BTC-USD.CC Exposure
0.0006294642833655295
CPER.US Exposure
-0.00036268685842052507
VIX.INDX Exposure
0.0005863548436814912
UUP.US Exposure
0.005813505193588101
TIP.US Exposure
0.017736977992547167
Idiosyncratic Exposure
0.10533048621894432
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
275.1%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$18.8M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+26.7%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-28.6%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
82.1% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
-0.81
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is bioAffinity Technologies, Inc. a high-risk investment?

bioAffinity Technologies, Inc. (BIAF.US) has an annualized volatility of 275.1% and experienced a maximum drawdown of 98.8% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of BIAF.US?

Over the past 10 years, BIAF.US has generated a Compound Annual Growth Rate (CAGR) of -61.9%. It has had a positive return in 25% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on bioAffinity Technologies, Inc.

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest